Experts suggest heart failure warning for Wegovy

An expert panel from the European Medicines Agency (EMA) has recommended that the Wegovy package leaflet should indicate its effectiveness against heart failure symptoms according to finance media Marketwire. In addition to heart failure, experts suggest that Wegovy can also improve motor functions in individuals with or without diabetes. Novo Nordisk, the manufacturer, stated that expanding the leaflet would improve treatment options for severely overweight individuals. Previously, the leaflet was updated to include a reduced risk of heart attacks and strokes in overweight patients with cardiovascular disease. In the US, following FDA approval, the leaflet was updated in March to include prevention of cardiovascular diseases, impacting insurance coverage. The EMA and EU Commission need to approve before the leaflet is expanded in the EU. In Denmark, patients typically pay for Wegovy themselves, which is prescribed for weight loss in individuals with a BMI over 30 or with conditions like diabetes or high blood pressure.